These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35649291)

  • 21. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I; Visalli M; Oteri R; Teti D; Venza M
    Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
    Kim SL; La MT; Shin MW; Kim SW; Kim HK
    Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells.
    Zhou W; Han H; Xu J; Sun T; Feng X
    Curr Pharm Des; 2021; 27(20):2366-2380. PubMed ID: 32787747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural Agents-Mediated Targeting of Histone Deacetylases.
    Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Thieno[2,3-
    Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
    J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
    Flis S; Gnyszka A; Flis K; Spławiński J
    Eur J Pharmacol; 2010 Feb; 627(1-3):26-32. PubMed ID: 19853597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.
    Jiang Q; Tang Y; Hu Q; Wang B; Ruan X; Zhou Q
    Eur J Med Chem; 2024 Apr; 269():116315. PubMed ID: 38503167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
    Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
    Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C
    Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
    Sonnemann J; Trommer N; Becker S; Wittig S; Grauel D; Palani CD; Beck JF
    Cancer Biol Ther; 2012 Apr; 13(6):417-24. PubMed ID: 22313685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of TRAIL-induced apoptosis by HDAC inhibitors.
    Fulda S
    Curr Cancer Drug Targets; 2008 Mar; 8(2):132-40. PubMed ID: 18336196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.